ProMIS Neurosciences reports interim Phase 1b data for PMN310 showing strong safety and biomarker signals
核心洞察
ProMIS Neurosciences reported strong interim safety and biomarker signals for PMN310, a differentiated antibody targeting toxic amyloid-beta oligomers (搜索), in a phase I-B Alzheimer's study.
Top-line results from the phase I-B trial are expected in the first quarter of 2027, according to the company's conference presentation.
The company said it is well-funded, advancing a robust pipeline, and planning for phase III development and commercial expansion.
ProMIS Neurosciences has reported strong interim safety and biomarker signals for PMN310, a differentiated antibody targeting toxic amyloid-beta oligomers (搜索), in a phase I-B study in Alzheimer's disease (搜索). The interim data were disclosed during the company's presentation at the 12th Annual Cantor Fitzgerald Global Healthcare Conference.
Top-line results from the phase I-B trial are expected in the first quarter of 2027. The company also stated that it is well-funded, is advancing a robust pipeline, and is planning for phase III development and commercial expansion.